查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1679269

血友病治疗市场预测至 2030 年：按血友病类型、治疗类型、给药途径、最终用户和地区进行的全球分析

Hemophilia Treatment Market Forecasts to 2030 - Global Analysis By Hemophilia Type (Hemophilia A, Hemophilia B, Hemophilia C, Acquired Hemophilia and Other Hemophilia Types), Treatment Type, Route of Administration, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2024 年全球血友病治疗市场价值为 137 亿美元，预计到 2030 年将达到 206 亿美元，预测期内的复合年增长率为 7.0%。血友病治疗包括治疗和预防血友病患者的过度出血，血友病是一种影响血液凝固的遗传性疾病。恢復正常血液凝固的主要策略是注射因子 VIII（用于治疗A型血友病 A）或因子 IX（用于B型血友病）进行替代疗法。其他治疗方法包括用于长期矫正的基因疗法、用于阻止血栓分解的抗纤维蛋白溶解药物以及用于较轻病例的去氨加压素 (DDAVP)。预防措施可以帮助减少不定期出血的发生频率。

血友病患病率不断上升

血友病患病率的不断上升正推动市场大幅成长。患者数量的不断增长推动了对先进治疗的需求，例如基因治疗、重组凝血因子和长半衰期疗法。随着患者知识的提高和诊断技术的进步，预防保健的采用正在增加。政府计划和医疗补贴也有助于市场扩张。製药公司正在投资尖端解决方案以满足不断增长的需求，加速市场扩张和可及性。

医疗费用高昂

治疗血友病的高费用限制了患者获得基本治疗的机会，阻碍了市场的成长。昂贵的因子替代疗法、基因疗法和长期治疗方法给医疗保健系统和患者带来了经济负担，尤其是在中低收入国家。这导致诊断率降低、治疗中断和对不充分的替代疗法的依赖，最终抑制了血友病治疗的市场扩张和创新。

扩大医疗基础设施

医疗保健基础设施的扩张透过改善人们获得先进药品、诊断设施和专科医生的机会，推动了该行业的发展。增加对诊所、医院和研究设施的投资将改善早期诊断和及时治疗，从而减少疾病的发生。官民合作关係、保险覆盖以及政府倡议都正在促进市场扩张。低温运输物流和配送网络的改善也将使凝血因子浓缩物和新型基因疗法药物更广泛地普及，特别是在开发中国家。

抑制剂开发的风险

抑制剂开发的风险可能会对血友病治疗市场产生负面影响，降低标准凝血因子疗法的有效性并增加治疗的​​复杂性和成本。产生抑制剂的患者需要昂贵的替代疗法，例如旁路疗法和基因疗法，这限制了市场的成长。此外，治疗抑制剂需要频繁监测和专门护理，这会对医疗资源造成压力。这些挑战阻碍了患者的治疗效果、阻碍了治疗的进行并减缓了整体市场的成长。

COVID-19 的影响

COVID-19 疫情导致诊断延迟、就诊人数减少、供应链受到影响，扰乱了血友病治疗市场。由于医疗机构关闭和医疗保健系统紧张，许多患者难以获得基本药物。然而，市场对家庭护理和数位健康解决方案的采用有所增加。随着医疗保健系统的復苏，需求也随之增长，推动了基因疗法和半衰期延长治疗的创新，以改善患者的治疗效果。

预测期内，基因治疗领域预计将占据最大的市场占有率

预计基因治疗领域将在预测期内占据最大的市场占有率，因为腺结合病毒(AAV) 的基因转移等先进疗法能够实现长期因子生产，从而改善患者的预后和生活品质。市场快速扩张的原因是核准数量的增加、研发支出的增加以及对治疗的需求不断增长。此外，与传统药物相比，基因疗法由于其终生成本效益高，在血友病治疗中变得越来越受欢迎。

预测期内，去氨加压素细分市场预计将以最高复合年增长率成长

预计去氨加压素部分在预测期内将呈现最高的成长率。这是因为去氨加压素促进血管性血友病因子和储存的第八因子的释放，从而降低出血风险和更频繁输注凝血因子的需要。去氨加压素易于给药，有註射剂和鼻内剂型，可提高患者的依从性。需求进一步受到认识度提高、新兴市场使用量成长和配方开发的影响，所有这些都对整个血友病治疗市场的成长产生了积极影响。

比最大的地区

在预测期内，预计北美将占据最大的市场占有率，因为血友病患病率的增加以及有利的报销政策正在推动市场成长。半衰期延长疗法和重组因子製剂等药物的进步正在改善治疗效果。此外，政府倡议和研究资金也支持创新。主要产业参与者和患者权益团体的存在进一步加速了市场扩张。个人化医疗的技术进步也有助于改善治疗效果。

复合年增长率最高的地区：

预计预测期内亚太地区将呈现最高的复合年增长率。这是因为医疗保健很容易获得，特别是在中国和印度等开发中国家。人们正在使用预防性治疗而不是按需治疗，基因和因子替代疗法的问题越来越少，需求也越来越大。此外，製药公司和医疗保健提供者之间的合作正在提高治疗方法的可用性，并且由于患有遗传性出血问题的老龄人口不断增加，市场也在不断扩大。

免费客製化服务：

订阅此报告的客户可享有以下免费自订选项之一：

  • 公司简介
    • 全面分析其他市场参与者（最多 3 家公司）
    • 主要企业的 SWOT 分析（最多 3 家公司）
  • 地理细分
    • 根据客户兴趣对主要国家进行的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争性基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第 2 章 前言

  • 概述
  • 相关利益者
  • 研究范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究资讯来源
    • 主要研究资讯来源
    • 二手研究资料资讯来源
    • 先决条件

第三章 市场走势分析

  • 驱动程式
  • 限制因素
  • 机会
  • 威胁
  • 最终用户分析
  • 新兴市场
  • COVID-19 的影响

第 4 章 波特五力分析

  • 供应商的议价能力
  • 买家的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

第 5 章 全球血友病治疗市场（依血友病类型划分）

  • A型血友病A
  • B型血友病
  • 血友病C
  • 后天性血友病
  • 其他类型的血友病

6. 全球血友病治疗市场依治疗类型划分

  • 因子替代治疗
    • 重组Ⅷ因子
    • 重组 IX 因子
    • 血浆衍生产品
    • 半衰期延长因子浓缩物
  • 去氨加压素
  • 基因治疗
  • 抗纤维溶解剂
  • 其他类型的治疗

7. 全球血友病治疗市场依给药途径划分

  • 静脉注射 (IV)
  • 皮下
  • 肌肉注射（IM）

8. 全球血友病治疗市场（依最终用户划分）

  • 医院
  • 血友病治疗中心
  • 居家护理
  • 门诊手术中心
  • 其他最终用户

9. 全球血友病治疗市场（按地区）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十章 主要进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十一章 公司概况

  • Takeda Pharmaceutical Company Limited
  • Octapharma AG.
  • CSL Behring
  • Medtronic
  • Pfizer, Inc.
  • Novo Nordisk A/S.
  • Bayer AG
  • Allergan
  • BioMarin
  • Aptevo Therapeutics
  • Spark Therapeutics, Inc.
  • AscellaHealth
  • Sanofi
  • Baxter International
  • F. Hoffmann La-Roche Ltd.
Product Code: SMRC28852

According to Stratistics MRC, the Global Hemophilia Treatment Market is accounted for $13.7 billion in 2024 and is expected to reach $20.6 billion by 2030 growing at a CAGR of 7.0% during the forecast period. Hemophilia treatment entails treating and preventing excessive bleeding in people who have hemophilia, a genetic illness that affects blood clotting. In order to restore normal clotting, the main strategy is replacement therapy, which involves injecting clotting factors VIII (for hemophilia A) or IX (for hemophilia B). Additional therapies include gene therapy for long-term correction, antifibrinolytic medications to stop clot breakdown, and desmopressin (DDAVP) for mild cases. Prophylactic (preventive) measures aid in lowering the frequency of unplanned bleeding episodes.

Market Dynamics:

Driver:

Increasing Prevalence of Hemophilia

The rising prevalence of hemophilia is fueling significant growth in the market. The need for advanced therapeutics, including as gene therapy, recombinant clotting factors, and longer half-life treatments, is being driven by an increase in the number of patients. Prophylactic treatment adoption is increasing as a result of increased patient knowledge and better diagnosis. Market expansion is also being aided by government programs and healthcare subsidies. Pharmaceutical firms are making investments in cutting-edge solutions to satisfy rising demand, which is speeding up market expansion and accessibility.

Restraint:

High Treatment Costs

The high cost of hemophilia treatment significantly hinders market growth by limiting patient access to essential therapies. Expensive clotting factor replacement therapies, gene therapies, and prolonged treatment regimens impose a financial burden on healthcare systems and patients, particularly in low- and middle-income countries. This leads to reduced diagnosis rates, treatment discontinuation, and reliance on inadequate alternatives, ultimately restraining market expansion and innovation in hemophilia care.

Opportunity:

Expanding Healthcare Infrastructure

Expanding healthcare infrastructure boosts the industry by increasing access to sophisticated medicines, diagnostic facilities, and specialist care. Investing more in clinics, hospitals, and research facilities improves early diagnosis and prompt treatment, which lowers problems. Public-private partnerships, insurance coverage, and government initiatives all contribute to market expansion. Better cold chain logistics and distribution networks also make clotting factor medicines and new gene therapies more widely available, especially in developing nations, which eventually improves patient outcomes and propels market expansion.

Threat:

Risk of Inhibitor Development

The risk of inhibitor development negatively impacts the hemophilia treatment market by reducing the effectiveness of standard clotting factor therapies, leading to increased treatment complexity and costs. Patients with inhibitors require alternative, expensive therapies like bypassing agents or gene therapy, limiting market growth. Additionally, managing inhibitors demands frequent monitoring and specialized care, straining healthcare resources. This challenge hinders patient outcomes, discourages treatment adoption, and slows overall market expansion.

Covid-19 Impact

The COVID-19 pandemic disrupted the hemophilia treatment market by delaying diagnoses, reducing hospital visits, and affecting supply chains. Many patients faced difficulties accessing essential therapies due to lockdowns and healthcare system strain. However, the market saw increased adoption of home-based treatments and digital health solutions. As healthcare systems recovered, demand rebounded, driving innovation in gene therapy and extended half-life treatments for improved patient outcomes.

The gene therapy segment is expected to be the largest market share during the forecast period

The gene therapy segment is expected to account for the largest market share during the forecast period because long-term factor production is made possible by advanced therapies such as adeno-associated virus (AAV)-based gene transfer, which enhances patient outcomes and quality of life. The market is expanding more quickly because of more approvals, higher R&D expenditures, and growing demand for curative treatments. Furthermore, gene therapy is becoming more and more popular in the treatment of hemophilia due to its lifetime cost-effectiveness when compared to traditional medicines.

The desmopressin segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the desmopressin segment is predicted to witness the highest growth rate, because desmopressin promotes the release of von Willebrand factor and stored factor VIII; it lowers the risk of bleeding and the frequency of clotting factor infusions. Patient compliance is improved by its simplicity of administration and availability in injectable and intranasal forms. Its demand is further fueled by growing awareness, growing use in emergency situations, and formulation developments, all of which have a favorable impact on the growth of the hemophilia treatment market as a whole.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share due to growing prevalence of hemophilia, along with favorable reimbursement policies, boosts market growth. Key pharmaceutical advancements, such as extended half-life therapies and recombinant factor products, enhance treatment efficacy. Additionally, government initiatives and research funding support innovation. The presence of major industry players, coupled with patient advocacy groups, further accelerates market expansion. Technological advancements in personalized medicine also contribute to improved treatment outcomes.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, because of easier access to care, especially in developing nations like China and India. Prophylactic treatments are increasingly being used instead of on-demand ones, which is decreasing problems and increasing, demand for gene therapy and factor replacement treatments. The availability of treatments is also being improved by partnerships between pharmaceutical companies and healthcare providers, and the market is expanding due to an older population with inherited bleeding problems.

Key players in the market

Some of the key players profiled in the Hemophilia Treatment Market include Takeda Pharmaceutical Company Limited, Octapharma AG., CSL Behring, Medtronic, Pfizer, Inc., Novo Nordisk A/S., Bayer AG, Allergan, BioMarin, Aptevo Therapeutics, Spark Therapeutics, Inc., AscellaHealth, Sanofi, Baxter International and F. Hoffmann La-Roche Ltd.

Key Developments:

In September 2024, Medtronic expanded aible spine surgery ecosystem with new technologies and Siemens Healthineers partnership, These enhancements are designed to advance AiBLE(TM), the Medtronic smart ecosystem of innovative navigation, robotics, data and AI, imaging, software and implants that enable more predictable outcomes in spine and cranial procedures.

In August 2024, Pfizer Inc. introduced PfizerForAll, a user-friendly digital platform designed to make access to healthcare and managing health and wellness more seamless for people across the U.S.

Hemophilia Types Covered:

  • Hemophilia A
  • Hemophilia B
  • Hemophilia C
  • Acquired Hemophilia
  • Other Hemophilia Types

Treatment Types Covered:

  • Factor Replacement Therapies
  • Desmopressin
  • Gene Therapy
  • Antifibrinolytics
  • Other Treatment Types

Administrations Covered:

  • Intravenous (IV) Administration
  • Subcutaneous (SC) Administration
  • Intramuscular (IM) Administration

End Users Covered:

  • Hospitals
  • Hemophilia Treatment Centers
  • Home Care
  • Ambulatory Surgical Centers
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Hemophilia Treatment Market, By Hemophilia Type

  • 5.1 Introduction
  • 5.2 Hemophilia A
  • 5.3 Hemophilia B
  • 5.4 Hemophilia C
  • 5.5 Acquired Hemophilia
  • 5.6 Other Hemophilia Types

6 Global Hemophilia Treatment Market, By Treatment Type

  • 6.1 Introduction
  • 6.2 Factor Replacement Therapies
    • 6.2.1 Recombinant Factor VIII
    • 6.2.2 Recombinant Factor IX
    • 6.2.3 Plasma-derived Products
    • 6.2.4 Extended Half-life Factor Concentrates
  • 6.3 Desmopressin
  • 6.4 Gene Therapy
  • 6.5 Antifibrinolytics
  • 6.6 Other Treatment Types

7 Global Hemophilia Treatment Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Intravenous (IV) Administration
  • 7.3 Subcutaneous (SC) Administration
  • 7.4 Intramuscular (IM) Administration

8 Global Hemophilia Treatment Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals
  • 8.3 Hemophilia Treatment Centers
  • 8.4 Home Care
  • 8.5 Ambulatory Surgical Centers
  • 8.6 Other End Users

9 Global Hemophilia Treatment Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Takeda Pharmaceutical Company Limited
  • 11.2 Octapharma AG.
  • 11.3 CSL Behring
  • 11.4 Medtronic
  • 11.5 Pfizer, Inc.
  • 11.6 Novo Nordisk A/S.
  • 11.7 Bayer AG
  • 11.8 Allergan
  • 11.9 BioMarin
  • 11.10 Aptevo Therapeutics
  • 11.11 Spark Therapeutics, Inc.
  • 11.12 AscellaHealth
  • 11.13 Sanofi
  • 11.14 Baxter International
  • 11.15 F. Hoffmann La-Roche Ltd.

List of Tables

  • Table 1 Global Hemophilia Treatment Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Hemophilia Treatment Market Outlook, By Hemophilia Type (2022-2030) ($MN)
  • Table 3 Global Hemophilia Treatment Market Outlook, By Hemophilia A (2022-2030) ($MN)
  • Table 4 Global Hemophilia Treatment Market Outlook, By Hemophilia B (2022-2030) ($MN)
  • Table 5 Global Hemophilia Treatment Market Outlook, By Hemophilia C (2022-2030) ($MN)
  • Table 6 Global Hemophilia Treatment Market Outlook, By Acquired Hemophilia (2022-2030) ($MN)
  • Table 7 Global Hemophilia Treatment Market Outlook, By Other Hemophilia Types (2022-2030) ($MN)
  • Table 8 Global Hemophilia Treatment Market Outlook, By Treatment Type (2022-2030) ($MN)
  • Table 9 Global Hemophilia Treatment Market Outlook, By Factor Replacement Therapies (2022-2030) ($MN)
  • Table 10 Global Hemophilia Treatment Market Outlook, By Recombinant Factor VIII (2022-2030) ($MN)
  • Table 11 Global Hemophilia Treatment Market Outlook, By Recombinant Factor IX (2022-2030) ($MN)
  • Table 12 Global Hemophilia Treatment Market Outlook, By Plasma-derived Products (2022-2030) ($MN)
  • Table 13 Global Hemophilia Treatment Market Outlook, By Extended Half-life Factor Concentrates (2022-2030) ($MN)
  • Table 14 Global Hemophilia Treatment Market Outlook, By Desmopressin (2022-2030) ($MN)
  • Table 15 Global Hemophilia Treatment Market Outlook, By Gene Therapy (2022-2030) ($MN)
  • Table 16 Global Hemophilia Treatment Market Outlook, By Antifibrinolytics (2022-2030) ($MN)
  • Table 17 Global Hemophilia Treatment Market Outlook, By Other Treatment Types (2022-2030) ($MN)
  • Table 18 Global Hemophilia Treatment Market Outlook, By Route of Administration (2022-2030) ($MN)
  • Table 19 Global Hemophilia Treatment Market Outlook, By Intravenous (IV) Administration (2022-2030) ($MN)
  • Table 20 Global Hemophilia Treatment Market Outlook, By Subcutaneous (SC) Administration (2022-2030) ($MN)
  • Table 21 Global Hemophilia Treatment Market Outlook, By Intramuscular (IM) Administration (2022-2030) ($MN)
  • Table 22 Global Hemophilia Treatment Market Outlook, By End User (2022-2030) ($MN)
  • Table 23 Global Hemophilia Treatment Market Outlook, By Hospitals (2022-2030) ($MN)
  • Table 24 Global Hemophilia Treatment Market Outlook, By Hemophilia Treatment Centers (2022-2030) ($MN)
  • Table 25 Global Hemophilia Treatment Market Outlook, By Home Care (2022-2030) ($MN)
  • Table 26 Global Hemophilia Treatment Market Outlook, By Ambulatory Surgical Centers (2022-2030) ($MN)
  • Table 27 Global Hemophilia Treatment Market Outlook, By Other End Users (2022-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.